What Liquid Cartilage™ actually is

Despite the name, Liquid Cartilage™ is not a supplement you order online or swallow with breakfast. It is a clinical treatment pathway whose flagship offering, ChondroFiller®, is an injectable acellular biologic collagen scaffold — a product that sits firmly in the medical device and orthobiologics category rather than the nutraceutical aisle.

The distinction matters. Glucosamine tablets, chondroitin capsules, and collagen drinks are oral products that enter the bloodstream through the gut. ChondroFiller® is delivered directly into a cartilage defect under ultrasound guidance, as an outpatient in-clinic procedure. Once placed, the scaffold gels within minutes, forming a structural matrix inside the defect that is designed to provide a framework within which the body's own cells can begin repair work.

In clinical classification terms, this places ChondroFiller® closer to a regenerative implant than to a nutritional product. The mechanism — filling a focal structural gap with a biologic scaffold — targets the defect site directly, rather than relying on oral absorption and systemic circulation to reach avascular cartilage tissue. That biological distinction is why the efficacy question for Liquid Cartilage™ requires a different frame of reference from the one applied to supplements. The two approaches are not competing versions of the same thing; they operate by entirely different principles.

Why knee cartilage is so hard to repair

Cartilage's resistance to self-repair comes down to two structural facts that have nothing to do with the severity of the damage or the quality of a person's diet.

First, articular cartilage — the smooth, load-bearing lining inside a joint — has no blood supply of its own. Biologists call this being avascular. Most tissues in the body receive a constant flow of blood that carries oxygen, nutrients, and the signalling molecules that kick off healing after injury. Cartilage does not. It draws nutrients instead from the synovial fluid that bathes the joint, a slower and less efficient supply chain that is simply not equipped to mount a meaningful repair response.

Second, the tissue contains very few active chondrocytes — the specialised cells responsible for producing and maintaining cartilage matrix. Where skin or bone can call on large populations of repair-ready cells, cartilage has only a sparse scattering of them, embedded in a dense matrix that limits their ability to migrate to a site of damage.

Together, these two features mean that once cartilage is significantly worn or defected, the body has almost no natural mechanism to restore it. This is also why oral supplements face a fundamental delivery problem: even if an ingredient has biological activity, reaching a focal cartilage defect via the gut, the bloodstream, and then through avascular tissue in useful concentrations is mechanistically implausible.

Injectable scaffold approaches are designed precisely to sidestep that barrier. By placing a repair matrix directly at the defect site, the treatment bypasses the circulatory route entirely — which is the core mechanistic argument for why local delivery matters in cartilage care.

What a collagen scaffold injection is designed to do

When a collagen scaffold is placed into a focal cartilage defect, it is not acting as a lubricant or an anti-inflammatory agent — it is performing a structural function. The scaffold occupies the physical space of the defect, providing a three-dimensional matrix within which the body's own repair cells can potentially migrate, settle, and begin producing new tissue. The goal, in plain terms, is to give the defect something to build within, rather than simply managing the pain that surrounds it.

Biologically, this matters because cartilage repair requires more than chemical signals — it requires architecture. Chondrocytes, the cells responsible for producing cartilage matrix, need a structural framework to anchor to and work within. By delivering a collagen-based matrix directly to the defect site, the approach aims to create the physical conditions for tissue ingrowth at the point where it is needed, rather than relying on the body to generate those conditions unaided.

Some injectable scaffold treatments are combined with biologic co-delivery techniques — including mesenchymal stem cell (MSC) approaches — to add cellular support alongside the scaffold's structural role. The rationale is that pairing architecture with appropriate biological inputs may more effectively promote cartilage-like tissue formation at the repair site.

This positions collagen scaffold treatment within the broader orthobiologics literature, where collagen-based matrices, MSC-based therapies, and combination approaches have been building a body of preclinical and early clinical evidence. Across that literature, scaffold-based repair is characterised as a credible frontier for focal cartilage defects — distinct in intent and mechanism from pain management or joint lubrication.

What the published record does not yet contain is an independent peer-reviewed randomised controlled trial on ChondroFiller® specifically. No such RCT has been published. The product-level case therefore rests on the wider scaffold evidence base and the clinic's own positioning. That is not unusual for emerging biologic implant products, and it does not make the mechanism implausible — but it is a meaningful transparency note for any patient weighing options.

Can oral supplements regrow cartilage — or only ease pain

For the millions of people managing knee pain day-to-day, oral supplements occupy a practical middle ground — more accessible than a clinic appointment, easier to sustain than physiotherapy alone. Glucosamine, chondroitin, MSM, oral hyaluronic acid, and undenatured type II collagen (UC-II) all have genuine roles in OA management, but the evidence for each is consistently symptomatic rather than structural.

Major health organisations and clinical evidence syntheses confirm that these ingredients can offer mild-to-moderate pain relief and some functional improvement for a proportion of OA patients. Oral hyaluronic acid, for instance, has performed better than placebo in randomised trials for knee pain and synovial symptoms. Glucosamine and chondroitin show chondroprotective signals in preclinical work. What none have demonstrated, in peer-reviewed human clinical trials, is the ability to rebuild lost cartilage tissue.

The biological reason loops back to the delivery problem outlined earlier: oral compounds must travel from gut to bloodstream to joint, and then somehow reach an avascular tissue in concentrations sufficient to drive structural repair. That route is not adequate for tissue regeneration.

UC-II is the most mechanistically nuanced ingredient in the group. At 40 mg daily, it works via oral tolerance — an immune-mediated pathway in which regulatory T-cells in gut-associated lymphoid tissue are recruited to dampen cartilage-specific inflammatory responses. A 2025 systematic review of 12 studies confirmed short- to mid-term benefits for pain, function, and range of motion. In a rat OA model, UC-II applied immediately after joint injury preserved articular cartilage integrity versus untreated controls. But this is chondroprotection — limiting ongoing destruction — not regrowth of tissue that has already been lost. That distinction matters clinically.

An ongoing randomised controlled trial is the first to include morphological knee changes as a secondary endpoint in UC-II research, which itself signals that definitive structural evidence in humans has not yet been established. Until such data emerge, the honest characterisation of oral supplements is: useful for symptom management in appropriate patients, but not a route to cartilage restoration.

Where injectable scaffolds sit among other injection options

The injectable landscape for knee joint problems spans several distinct mechanisms — and the choice between them is not simply a matter of preference or price, but of what the treatment is actually designed to do.

Hyaluronic acid (viscosupplementation) works by replenishing the synovial fluid's lubricating properties, reducing friction and improving the mechanical environment inside the joint. It is palliative: guideline support is mixed across major bodies, and it does not repair cartilage tissue.

Corticosteroid injections target inflammation directly and have a well-established role in managing acute flares and reducing joint swelling. Their limitation is durability — they are not a long-term cartilage solution, and repeated use carries its own considerations.

Platelet-rich plasma (PRP) sits in a regenerative-leaning category. It delivers concentrated growth factors from a patient's own blood into the joint, with some published evidence for pain and function benefit. However, preparation protocols vary significantly between clinics, and the evidence base remains mixed depending on the protocol used.

Arthrosamid® (polyacrylamide hydrogel) is a filler-style implant that integrates into the synovial tissue and may modify symptoms over a sustained period. It is non-regenerative — its mechanism is distinct from a collagen scaffold in that it does not aim to occupy or bridge a structural defect in the cartilage surface itself.

Injectable collagen scaffolds occupy a different category from all of the above. Their purpose is structural: to fill a focal cartilage defect, provide an architectural matrix, and support the migration and activity of the body's own repair cells. This is a mechanistically separate intent from lubricating, anti-inflammatory, or hydrogel-filler approaches.

No single pathway is universally appropriate. Which option — or combination — applies depends on the nature and extent of the cartilage problem, a patient's activity level, and other clinical factors that a thorough assessment is needed to determine.

Who injectable cartilage scaffolds are most likely to suit

Scaffold-based treatment targets a specific problem: a discrete, contained area of cartilage damage. That precision is a clinical strength, but it also means the approach has a defined patient profile — and being clear about that profile is part of giving patients a realistic picture of their options.

Patients most likely to be considered

Typically, suitable candidates share several features: a confirmed focal cartilage defect rather than widespread joint degeneration, a relatively intact surrounding cartilage bed, and a joint that retains reasonable space. Younger or more active patients — including those whose damage stems from a sports injury or traumatic event rather than longstanding degenerative wear — tend to fall more naturally within the focal-defect indication. This reflects the biological logic: a scaffold provides a framework for repair, and that framework is most useful when the surrounding tissue environment is still viable enough to support it.

Where scaffolds are generally not indicated

Diffuse osteoarthritis with significant joint space loss, or bone-on-bone arthritis distributed across the joint, falls outside the focal-defect rationale. Patients who have already undergone joint replacement surgery are similarly not candidates. In these cases, the structural environment the scaffold depends on is no longer present, and the treatment's premise does not hold.

Before any treatment is planned, imaging — typically MRI — is used to assess the defect's size, depth, and the quality of the surrounding cartilage. That assessment determines not just whether a scaffold approach is appropriate, but which specific technique is likely to fit the defect architecture.

For most patients with diffuse OA, the scaffold indication simply does not apply. For those with a confirmed focal defect and an otherwise functional joint, it remains one of the few options that directly addresses the structural gap rather than managing the symptoms around it — which is why a thorough clinical assessment is the necessary first step before any pathway decision is made.

1. [1] Undenatured type II collagen for knee osteoarthritis. (2025). https://doi.org/10.1080/07853890.2025.2493306 https://doi.org/10.1080/07853890.2025.2493306
2. [2] Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat OA model. (2017). https://doi.org/10.1016/j.joca.2017.08.013 https://doi.org/10.1016/j.joca.2017.08.013